Fennec Pharmaceuticals Announces Participation in Key Conference
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a dynamic specialty pharmaceutical company recognized for its innovative approaches, has made a noteworthy announcement regarding its upcoming engagement in a significant investor conference. The company is set to participate in the 15th Annual Craig-Hallum Alpha Select Conference, which serves as a critical forum for connecting with investors and discussing advancements in the pharmaceutical sector.
Engagement at the Craig-Hallum Alpha Select Conference
This year, management from Fennec Pharmaceuticals will be available for private one-on-one meetings during the conference. Such interactions are invaluable for fostering relationships and sharing insights into the company's strategic directions and product developments.
Conference Overview
Event: 15th Annual Craig-Hallum Alpha Select Conference
Date: November 19, 2024
Venue: Sheraton New York Times Square Hotel, New York City
Advancements in Pediatric Care
Fennec Pharmaceuticals is committed to addressing significant health challenges, notably in pediatric medicine. The company's flagship product, PEDMARK, is designed to mitigate the risk of platinum-induced ototoxicity in young patients undergoing cancer treatment. This treatment has been a breakthrough for families facing the daunting effects of chemotherapy on hearing.
Recent Regulatory Approvals
PEDMARK has achieved remarkable milestones, having received FDA approval in 2022, followed by approvals from the European Commission and the United Kingdom in subsequent years. Under the brand name PEDMARQSI, this medication now enjoys pediatric use marketing authorization, ensuring vital access for those in need.
Fennec Pharmaceuticals' Commitment to Innovation
With Orphan Drug Exclusivity granted in the U.S., Fennec Pharmaceuticals has secured a competitive advantage that ensures the uninterrupted supply of PEDMARK to at-risk populations. The company's ongoing research and development reflect its commitment to expanding its therapeutic arsenal and improving patient outcomes.
Connecting with Fennec Pharmaceuticals
For stakeholders and interested parties seeking to learn more, Fennec Pharmaceuticals has made their team readily accessible. Robert Andrade, the Chief Financial Officer, represents the investor communication front, making him a valuable contact for inquiries related to the company’s financial health and strategic goals.
Looking Ahead
As Fennec Pharmaceuticals participates in this upcoming conference, it signals a promising opportunity to enhance visibility among investors and stakeholders. The insights shared during this event will undoubtedly underline the company's dedication to providing therapies that enhance the quality of life for patients battling severe conditions.
Frequently Asked Questions
What is the Craig-Hallum Alpha Select Conference?
The Craig-Hallum Alpha Select Conference is a prominent event where investors and companies meet to discuss financial performance, collaborative opportunities, and advancements in various industries.
What is PEDMARK?
PEDMARK is a pharmaceutical product developed by Fennec Pharmaceuticals, aimed at reducing the risk of hearing loss in pediatric patients receiving platinum-based chemotherapy.
When did PEDMARK receive FDA approval?
PEDMARK received FDA approval in September 2022 and continues to be a significant treatment option for at-risk children.
How can investors contact Fennec Pharmaceuticals?
Investors interested in connecting with Fennec Pharmaceuticals can reach out to Robert Andrade, the Chief Financial Officer, at +1 919-246-5299.
What is the significance of Orphan Drug Exclusivity?
Orphan Drug Exclusivity enables Fennec Pharmaceuticals to market PEDMARK without competition for a specified period, enhancing access to critical therapies for underserved populations.
